Do GLP-1 Drugs Reduce Cancer Risk? A 2026 Evidence-Based Metabolic Oncology Review

By Editorial Team

GLP-1 receptor agonists such as Semaglutide and Tirzepatide have transformed the treatment of obesity and type 2 diabetes.

As their use expands globally, a critical question is emerging:

Do GLP-1 drugs reduce cancer risk — or is any apparent benefit simply a consequence of weight loss and improved metabolic health?

This article reviews:

  • The established link between obesity and cancer

  • The biological mechanisms affected by GLP-1 therapy

  • Human clinical trial data

  • Observational cancer incidence studies

  • Safety signals (including thyroid cancer)

  • What remains unknown

All claims below are supported by peer-reviewed sources.

1. Obesity and Cancer: Established Evidence

The link between obesity and cancer is well established. The International Agency for Research on Cancer concluded in 2016 that excess body fat increases the risk of at least 13 cancers (1).

Key cancers linked to obesity include:

  • Colorectal

  • Postmenopausal breast

  • Endometrial

  • Pancreatic

  • Liver

Mechanisms supported by human and translational data include:

Hyperinsulinemia

Chronic elevation of insulin increases signaling through:

  • Insulin receptor

  • IGF-1 receptor

  • PI3K–AKT–mTOR pathway

This growth signaling axis is central in many tumors (2).

Chronic Inflammation

Obesity-associated adipose tissue produces inflammatory cytokines contributing to tumor-promoting environments.

These mechanisms provide a biologically plausible basis for cancer risk reduction if metabolic dysfunction is reversed.

2. What GLP-1 Drugs Do Mechanistically

GLP-1 receptor agonists:

  • Reduce appetite

  • Lower caloric intake

  • Decrease body weight

  • Improve insulin sensitivity

  • Reduce fasting insulin levels

Semaglutide weight-loss data come from the STEP program (3).

Tirzepatide weight-loss data come from SURMOUNT-1 (4).

Neither trial was designed to assess cancer outcomes.

3. Randomized Controlled Trial Data on Cancer Outcomes

Major cardiovascular outcome trials include:

  • SUSTAIN-6 (5)

  • REWIND (6)

  • LEADER (7)

These trials did not demonstrate increased overall cancer incidence.

Importantly:

  • Follow-up was typically 2–5 years.

  • Cancer incidence was not a primary endpoint.

  • Trials were underpowered for cancer prevention conclusions.

Conclusion: No convincing signal of increased overall cancer risk in RCTs.

But these data do NOT prove cancer prevention.

4. Observational Cancer Incidence Studies

Several large real-world database studies have examined cancer outcomes in GLP-1 users versus other diabetes therapies.

For example:

  • Studies comparing GLP-1 receptor agonists to insulin or sulfonylureas have shown neutral or reduced colorectal cancer risk (e.g., Suissa et al., Diabetes Care, 2012; though earlier GLP-1 era data are limited).

More recent population studies (2023–2024) suggest neutral to modestly reduced obesity-related cancer incidence, but follow-up remains relatively short.

Important caveat:

Observational data cannot establish causality due to:

  • Confounding by indication

  • Healthier user bias

  • Short exposure duration

As of 2026, no large randomized cancer-prevention trial of GLP-1 drugs exists.

5. Thyroid Cancer Signal

Rodent studies demonstrated C-cell hyperplasia and medullary thyroid carcinoma with GLP-1 agonists.

However, human data have not demonstrated a clear increase in medullary thyroid cancer incidence.

A systematic review:

Regulatory agencies continue to include warnings for patients with:

  • Personal or family history of medullary thyroid carcinoma

  • MEN2 syndrome

No large epidemiologic dataset has confirmed a definitive increased risk in humans.

6. Lean Mass Loss and Cancer Risk

Weight loss with GLP-1 therapy includes lean mass reduction.

In the STEP 1 body composition substudy (9):

  • Approximately 39% of weight loss was lean mass.

Loss of skeletal muscle (sarcopenia) is associated with (10):

  • Poorer cancer survival

  • Reduced chemotherapy tolerance

This does not prove GLP-1 increases cancer risk, but it highlights a potential trade-off requiring further study.

7. Does Weight Loss Reduce Cancer Risk?

Intentional weight loss has been associated with reduced cancer incidence in large prospective cohorts. (12)

These data suggest that sustained metabolic improvement reduces cancer risk.

Whether GLP-1 pharmacologic weight loss produces the same long-term effect remains unknown.

8. What We Can Conclude (Evidence-Based)

Based on available data:

  1. GLP-1 receptor agonists have not demonstrated increased overall cancer risk in randomized trials.

  2. There is biologic plausibility for reduced obesity-related cancer risk.

  3. Long-term randomized cancer-prevention trials do not yet exist.

  4. Observational data suggest neutral to possibly reduced risk, but are not definitive.

  5. Lean mass reduction introduces an important physiological variable requiring further study.

The most accurate summary:

GLP-1 drugs improve metabolic risk factors linked to cancer, but they are not proven cancer-prevention medications.

9. What Is Still Unknown (2026 Research Gaps)

  • 10–15 year cancer incidence outcomes

  • Cancer recurrence data in survivors

  • Interaction with immunotherapy

  • Long-term durability after discontinuation

  • Muscle-preserving strategies during therapy

Until long-term prospective oncology-specific trials are completed, conclusions must remain cautious.

Final Takeaway

GLP-1 drugs represent a powerful metabolic intervention.

Because obesity and hyperinsulinemia promote tumorigenesis, correcting these abnormalities may reduce cancer risk.

However:

  • Evidence supports metabolic plausibility, not definitive prevention.

  • No high-quality RCT has demonstrated reduced cancer incidence as a primary outcome.

  • Long-term safety surveillance remains ongoing.

The emerging paradigm is not that GLP-1 drugs are anti-cancer therapies.

It is that metabolic normalization may alter cancer biology — and GLP-1 drugs are one tool within that broader framework.


References

  1. Lauby-Secretan B, Scoccianti C, Loomis D, Grosse Y, Bianchini F, Straif K. Body fatness and cancer—viewpoint of the IARC Working Group. N Engl J Med. 2016;375(8):794–798. doi:10.1056/NEJMsr1606602

  2. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer. 2008;8(12):915–928. doi:10.1038/nrc2536

  3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183

  4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216. doi:10.1056/NEJMoa2206038

  5. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa1607141

  6. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND). Lancet. 2019;394(10193):121–130. doi:10.1016/S0140-6736(19)31149-3

  7. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa1603827

  8. Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract. 2012;98(2):271–284. doi:10.1016/j.diabres.2012.07.008

  9. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA. 2021;325(14):1403–1413. doi:10.1001/jama.2021.1831

  10. Prado CM, Baracos VE, McCargar LJ, et al. Body composition as an independent determinant of 5-fluorouracil–based chemotherapy toxicity. Lancet Oncol. 2007;8(7):629–636. doi:10.1016/S1470-2045(07)70152-9

  11. Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357(8):753–761. doi:10.1056/NEJMoa066603

  12. Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–651. doi:10.1056/NEJMoa1600869

Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Fenbendazole and the Joe Tippens Protocol: Evidence, Risks, and Current Perspective (2026 Update)

By Editorial Team
Image
Introduction The Joe Tippens Protocol revolves around the off-label use of fenbendazole (a veterinary dewormer commonly sold as Panacur C or Safe-Guard) combined with various supplements for cancer. Joe Tippens popularized this approach after claiming it contributed to his remission from metastatic small-cell lung cancer in 2017. As of 2025, Joe Tippens remains alive and reports being cancer-free for over 8 years, continuing a maintenance version of the protocol. Fenbendazole is marketed for animals (e.g., Panacur C, Safe-Guard ) and has no regulatory approval for human cancer treatment . Evidence for anticancer effects is primarily preclinical or anecdotal , and clinical trials in humans are lacking. Important Disclaimer: Fenbendazole is not approved by the FDA, EMA, or any regulatory body for human use or cancer treatment. There are no completed randomized controlled human clinical trials demonstrating its safety or efficacy against cancer. All human evidence is anecdotal, from case...
Read more

Fenbendazole and Ivermectin for Cancer: A Case Series of Over 360 Patients (2026)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. There are presently over 1,500 herbs and food supplements in commerce, many of them with claims in use against cancer. This guide compiles over 500 scientific r...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

Fenbendazole and Cancer: What the Science Really Shows (Evidence, Risks & Open Questions)

By Editorial Team
Image
Abstract Background:  Fenbendazole (FBZ), a benzimidazole anthelmintic approved for veterinary use, has attracted attention for potential anticancer activity based on laboratory findings and widespread anecdotal reports.  Objective:  To critically appraise the current evidence on fenbendazole and cancer using a peer‑review style framework.  Methods:  Narrative review of preclinical studies, publicly reported human case narratives, and safety signals, with emphasis on evidence hierarchy and translational limitations.  Results:  Preclinical data demonstrate antiproliferative effects via microtubule disruption and metabolic stress in vitro and in animal models. Human evidence is limited to uncontrolled case reports; no Phase I–III clinical trials or regulatory approvals for oncology exist. Safety data in humans are sparse, with hepatotoxicity signals reported.  Conclusions:  Fenben...
Read more

Best Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is a broad spectrum anti-parasitic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. (2) Fenbendazole, has garnered ⁤attention​ for its potential use ​in‍ humans.‍ The Fenbendazole Cancer Protocol gained rapid interest over the past years following some  fenbendazole advanced cancer success stories . Joe Tippens founded the protocol  after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discover...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...
Read more